Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

about

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.The Eosinophil: for better or worse, in sickness and in health.

P2860

Q52571066-39B945B9-388A-494A-890F-6B1454BC13E7 Q52729256-AB5BE78A-88BB-4C76-89B0-688BD0DD9200

P2860

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

Item

http://www.wikidata.org/entity/Q47848286

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

@en

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

@nl

type

Item

label

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

@en

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

@nl

prefLabel

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

@en

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

@nl

P1476

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

@en

P2093

Amy D Klion

http://www.w3.org/2001/XMLSchema#string

Fei Li Kuang

http://www.w3.org/2001/XMLSchema#string

P2860

Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis

Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

Familial eosinophilia: a benign disorder?

Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Dysregulation of interleukin 5 expression in familial eosinophilia.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

A pilot study of omalizumab in eosinophilic esophagitis

P304

1502-1509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JAIP.2017.08.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29122152

http://www.w3.org/2001/XMLSchema#string

P932

5718167

http://www.w3.org/2001/XMLSchema#string

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

about

P2860

P2860

Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932